Interim Management Statement

FINSBURY WORLDWIDE PHARMACEUTICAL TRUST PLC                  

      Interim Management Statement - 3 months to 30 June 2009 (unaudited)      

Finsbury Worldwide Pharmaceutical Trust PLC invests in pharmaceutical, 
biotechnology and related companies worldwide with the aim of achieving a high
level of capital growth.

The 3 month period ending 30 June 2009 was a challenging one for the Company
due in part to a rotation by investors out of healthcare stocks back into the
broader market and also an appreciation of sterling against the US$ in the
period. The Company's undiluted net asset value per share fell by 6.3% and the
share price by 4.1%, compared to a fall of 5.4% in the Company's benchmark, the
DataStream World Pharmaceutical and Biotechnology Index measured in sterling
terms on a total return basis.

During the three-month period a total of 1,893,097 shares were repurchased,
927,347 to be held in treasury and 965,750 were cancelled as the 10% treasury
limit had been reached. Since the period end, to 10 August 2009, 376,425 shares
have been bought back for cancellation and, following the cancellation of all
of the Company's shares held in treasury on 20 July 2009, 783,000 shares have
been bought back to be held in treasury. The shares repurchased during the
period and up to 10 August 2009 were done so at a cost of £15.98m (including
expenses).

In the period from 30 June 2009 to 10 August 2009, the Company's diluted net
asset value per share and the share price both rose by 5.7% and 4.3%
respectively compared to a rise of the 6.4% in the Company's benchmark, all
measured on a total return basis.

Following the final exercise date of the Company's warrants on 31 July 2009,
10,745,610 new shares were allotted by the Company on 5 August 2009 raising £
49.86m.

On 22 May 2009 the Company announced that it was considering proposals for a
bonus issue of subscription shares to ordinary shareholders following the final
exercise date of the Company's warrants on 31 July 2009. Full details of the
proposed bonus issue of subscription shares were published on 11 August 2009.

At the Company's Annual General Meeting, held on 17 July 2009, all of the
resolutions were passed

Trust Characteristics

                           30 June 2009              31 March 2009             
                                                                               
Number of holdings         44                        40                        
                                                                               
Net assets (£m)            232.9                     260.5                     
                                                                               
Net yield                  0.6%                      0.5%                      
                                                                               
Gearing (AIC basis)        115                       112                       
                                                                               
Share price (p)            528.00                    550.50                    
                                                                               
NAV (p) -undiluted         590.17                    629.73                    
                                                                               
NAV (p) diluted: warrants  563.17                    595.55                    
                                                                               
NAV (p) - fully diluted    560.58                    593.06                    
for                                                                            
                                                                               
warrants and treasury                                                          
shares                                                                         
                                                                               
(Discount)/premium         (10.5%)                   (12.6%)                   
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted  (6.2%)                    (7.6%)                    
- warrants)                                                                    
                                                                               
(Discount/premium (fully   (5.8%)                    (7.2%)                    
diluted)                                                                       
                                                                               
Warrant price (p)          50.50                     62.00                     

Source: Frostrow Capital LLP

10 Largest Investments

Name                                 % of                      % of           
                                                                              
                             investment portfolio      investment portfolio   
                                                                              
                                at 30 June 2009          at 31 March 2009     
                                                                              
Roche                                 7.5            3.3                      
                                                                              
Novartis                              6.5            6.3                      
                                                                              
Johnson & Johnson                     5.3            0.9                      
                                                                              
Gilead Sciences                       5.2            5.3                      
                                                                              
Bristol-Myers Squibb                  4.9            5.5                      
                                                                              
Wyeth                                 4.4            4.3                      
                                                                              
Shionogi                              3.9            3.6                      
                                                                              
Biogen Idec                           3.2            3.8                      
                                                                              
Amgen                                 3.2            4.0                      
                                                                              
Vertex Pharmaceuticals                3.1            3.8                      
                                                                              
Total                                47.2            40.8                     
                                                                              

Source: Frostrow Capital LLP

Sector Analysis

                                      % of                       % of           
                                                                                
                              investment portfolio       investment portfolio   
                                                                                
                                at 30 June 2009            at 31 March 2009     
                                                                                
Large capitalisation                  64.2                       56.9           
                                                                                
Small capitalisation                  35.8                       43.1           
                                                                                
Total                                100.0                      100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                             investment portfolio       investment portfolio   
                                                                               
                               at 30 June 2009            at 31 March 2009     
                                                                               
North America                        68.2                       66.2           
                                                                               
Europe                               21.3                       25.4           
                                                                               
Japan                                10.5                       8.4            
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     -3.2%           +19.5%          +11.6%          +15.2%         
                                                                               
NAV Fully       -5.0%           +16.4%          +15.9%          +18.1%         
diluted                                                                        
                                                                               
Benchmark*      -5.4%           +8.5%           +3.9%           +20.5%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Fundamental Data. Benchmark - Thomson Reuters.

* Benchmark - Datastream World Pharmaceutical and Biotechnology Index measured
in sterling terms on a total return basis.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.finsburywp.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Warrants - 8038453

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

14 August 2009